FDA Hands Fast-Pass Voucher for Bizarre Rare Kid Disease Drug
Published Date: 1/21/2026
Notice
Summary
The FDA just gave a special fast-track ticket called a Priority Review Voucher to UCB, Inc. for their rare pediatric disease drug KYGEVVI, approved in November 2025. This voucher helps speed up future drug reviews, saving time and potentially money for the company. It’s a big win for patients with thymidine kinase 2 deficiency and a boost for UCB’s innovation efforts.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
KYGEVVI Approved for TK2 Deficiency
KYGEVVI (doxecitine and doxribtimine) was approved November 3, 2025, to treat thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients whose symptoms began at age 12 years or younger. The approval covers both adult patients and pediatric-onset cases with symptom onset on or before 12 years.
Priority Review Voucher Issued to UCB
The FDA issued a Rare Pediatric Disease Priority Review Voucher to the sponsor of KYGEVVI (doxecitine and doxribtimine). KYGEVVI was approved November 3, 2025, and the voucher is now formally awarded under section 529 of the FD&C Act.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-01063, Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is checking in on a paperwork process that helps businesses and nonprofits sort out application conflicts. They want your thoughts on how to make this easier and clearer, especially for small businesses. Comments are open until March 23, 2026, so don’t miss your chance to weigh in and help save time and hassle!
Next: 2026-01067, Advisory Committee on the Readjustment of Veterans, Notice of Meeting
The Advisory Committee on the Readjustment of Veterans will meet online on March 24, 2026, to review their latest report and plan future meetings. This group helps the VA improve benefits and services for Veterans adjusting to civilian life, especially those who served in combat. The public can join, share comments, and help shape how Veterans get support—no money changes announced, but your voice matters!